Established Cardiovascular Disease: How to Prep for Your First Visit

What "Established Cardiovascular Disease" Actually Means

Established CVD is not a single diagnosis. It is a cluster of atherosclerotic conditions that share one thing: documented, clinically significant disease that has already caused an event or produces symptoms. Physicians use this term because it signals the highest tier of cardiovascular risk, requiring the most aggressive medical targets.

The four main categories recognized in major guidelines are:

• Prior myocardial infarction (MI): Documented ST-elevation or non-ST-elevation MI confirmed by troponin rise and imaging [1]
• Prior ischemic stroke or TIA: Confirmed by neuroimaging or clinical criteria [2]
• Peripheral arterial disease (PAD): Ankle-brachial index <0.9, or prior peripheral revascularization [3]
• Symptomatic coronary artery disease (CAD): Stable angina confirmed by stress testing or coronary angiography [4]

Why the Distinction Matters Clinically

Patients with established CVD are classified as "very high risk" by the 2021 ESC Guidelines on Cardiovascular Disease Prevention [5]. That classification changes LDL targets, blood pressure goals, and which add-on therapies are indicated. It also determines eligibility for trials like SELECT.

What Is NOT Established CVD

Risk factors alone, such as hypertension, smoking history, or a calcium score, do not constitute established CVD. Neither does a family history of heart disease. The distinction between primary prevention and secondary prevention is the presence of a clinical event or objective evidence of flow-limiting disease [1].

Records and Documents to Gather Before Your Appointment

Bring everything. Physicians spend a disproportionate share of first visits reconstructing history that patients have in file cabinets or hospital portals. Organizing this material in advance allows the clinician to spend the appointment on decisions, not data entry.

Cardiac Imaging and Procedural Reports

Gather any echocardiogram reports showing ejection fraction, wall motion abnormalities, or valvular disease. If you have had a cardiac catheterization or PCI, bring the cath report including the percent stenosis of each vessel and which stents were placed. Coronary CT angiography reports are equally useful [6].

The ACC/AHA 2023 Guideline for the Management of Patients with Chronic Coronary Disease states that documenting prior revascularization history is a class I recommendation before initiating or modifying antiplatelet therapy [4].

Lab Work From the Past 12 Months

Bring printed or digital copies of:

• Fasting lipid panel (LDL-C, HDL-C, triglycerides, total cholesterol)
• HbA1c and fasting glucose
• Comprehensive metabolic panel (creatinine, eGFR, liver enzymes)
• TSH
• High-sensitivity CRP if previously measured

The 2021 ESC guideline sets an LDL-C target of <1.4 mmol/L (<55 mg/dL) for very-high-risk patients, with a secondary target of at least 50% reduction from baseline [5]. If your most recent LDL is above that threshold, your clinician will want to know your current statin dose and whether you have tried ezetimibe or a PCSK9 inhibitor.

Discharge Summaries and Operative Notes

Hospital discharge summaries contain the exact diagnosis codes, the medications started at discharge, and any follow-up instructions given at the time of your event. Operative notes from bypass surgery or valve replacement list graft locations and prosthetic valve types, information that affects anticoagulation decisions for years afterward [7].

Building a Complete Medication List

Medication reconciliation errors are among the most common sources of preventable harm in cardiovascular care [8]. Come with a written list, not just the bottles.

What to Include for Each Drug

For every medication, write down:

1. Generic name and brand name
2. Dose in milligrams
3. Frequency (once daily, twice daily, as needed)
4. Prescribing physician
5. How long you have been taking it

High-Alert Cardiovascular Medications

Some drugs require special attention at a first visit. Warfarin requires a recent INR. Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran) require current renal function. Amiodarone requires TSH and liver function tests. Digoxin requires a recent level and potassium. Bring results for all of these if you take them [9].

The FDA label for apixaban (Eliquis) specifies dose reduction criteria based on age, weight, and serum creatinine, so your clinician needs current values to confirm you are on the correct dose [10].

Understanding Your Cardiovascular Risk Score

Residual risk after an event is not uniform. Two patients who both had an MI five years ago may have very different five-year mortality trajectories depending on ejection fraction, diabetes status, smoking, blood pressure control, and LDL achieved on therapy.

TIMI, GRACE, and HEART Scores

The TIMI Risk Score for UA/NSTEMI and the GRACE 2.0 score are validated tools for estimating in-hospital and one-year mortality after an acute coronary syndrome [11]. If your event was recent, your discharge summary may already include one of these scores. Bring it.

Framingham and ASCVD Pooled Cohort Equations

For longer-term risk, the ACC/AHA Pooled Cohort Equations estimate 10-year ASCVD risk. The AHA notes that patients with established CVD are by definition at high or very-high risk and do not need this calculator to determine statin eligibility, though it may be used to guide shared decision-making about additional therapies [1].

HealthRX First-Visit Cardiovascular Risk Snapshot Framework

Before your appointment, fill in these six values so your clinician has them at a glance:

| Parameter | Your Value | Guideline Target | |---|---|---| | LDL-C (mg/dL) | ___ | <55 mg/dL | | Blood pressure (mmHg) | ___ | <130/80 | | HbA1c (%) | ___ | <7.0 (if diabetic) | | BMI (kg/m²) | ___ | 18.5-24.9 | | Smoking status | ___ | Non-smoker | | eGFR (mL/min/1.73m²) | ___ | >60 |

Bringing these numbers filled in saves 10-15 minutes of data entry and gets the conversation to treatment faster.

Semaglutide and the SELECT Trial: What Every CVD Patient Should Know

The SELECT trial changed the treatment field for patients with established CVD who carry excess weight. This is one of the most consequential cardiovascular outcomes trials published in recent years, and many patients arrive at their first visit unaware of it.

What SELECT Found

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity, N=17,604) enrolled adults with a BMI ≥27, established CVD, and no history of diabetes. Participants were randomized to semaglutide 2.4 mg subcutaneous weekly or placebo on top of standard of care [12].

The primary endpoint, a composite of cardiovascular death, non-fatal MI, or non-fatal stroke (MACE-3), occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group over a median follow-up of 39.8 months. That is a 20% relative risk reduction (HR 0.80; 95% CI 0.72-0.90; P<0.001) [12].

The trial also showed reductions in all-cause mortality and heart failure hospitalization as secondary endpoints, though the trial was not powered for those outcomes individually [12].

FDA Approval Status

The FDA approved semaglutide 2.4 mg (Wegovy) for cardiovascular risk reduction in adults with established CVD and BMI ≥27 in March 2024, making it the first weight-management medication to carry a cardiovascular outcomes indication [13].

The FDA label states: "Wegovy is indicated to reduce the risk of serious cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity (BMI ≥30) or overweight (BMI ≥27) who also have at least one weight-related condition" [13].

Who Qualifies at a First Visit

To discuss semaglutide for CVD risk reduction at your first visit, confirm you meet all three criteria:

1. Documented established CVD (MI, stroke, PAD, or symptomatic CAD)
2. BMI ≥27 kg/m²
3. No current diagnosis of type 1 or type 2 diabetes (though a separate indication exists for type 2 diabetes with CVD via the 1.0 mg dose studied in SUSTAIN-6)

If you meet these criteria, ask your clinician directly whether semaglutide is appropriate given your current medication list, eGFR, and GI history [14].

Blood Pressure and Lipid Targets: Know Your Numbers Before You Arrive

Blood Pressure Goals

The 2017 ACC/AHA Hypertension Guideline defines high blood pressure as ≥130/80 mmHg and recommends a target of <130/80 mmHg for patients with established CVD [15]. Check your blood pressure at home on three separate mornings before your visit and bring the average. Home readings reduce white-coat effect and give the clinician a more accurate picture than a single office reading.

The SPRINT trial (N=9,361) demonstrated that intensive systolic blood pressure targets below 120 mmHg reduced cardiovascular events by 25% compared to a target of 140 mmHg (HR 0.75; 95% CI 0.64-0.89; P<0.001) in high-risk patients, though that trial excluded patients with prior stroke [16].

LDL-C Goals and Statin Intensity

The ACC/AHA 2022 Guideline on Cholesterol recommends high-intensity statin therapy for all patients with established ASCVD as a class I recommendation [17]. High-intensity means rosuvastatin 20-40 mg or atorvastatin 40-80 mg daily.

If LDL-C remains ≥70 mg/dL on maximally tolerated statin therapy, the guideline recommends adding ezetimibe 10 mg daily as a class IIa recommendation [17]. If LDL-C still exceeds 70 mg/dL after statin plus ezetimibe, a PCSK9 inhibitor (evolocumab or alirocumab) may be considered. The FOURIER trial (N=27,564) showed evolocumab reduced MACE by 15% on top of statin therapy (HR 0.85; 95% CI 0.79-0.92; P<0.001) [18].

Antiplatelet and Anticoagulation Therapy: Questions to Prepare

Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) is standard after ACS or PCI. The duration of DAPT is one of the most common discussions at a first visit with a new cardiologist [4].

Key Questions to Ask

• How long should I continue dual antiplatelet therapy?
• Should I be on aspirin indefinitely?
• Do I need anticoagulation in addition to antiplatelet therapy?
• Does my stent type affect how long I need DAPT?

The ACC/AHA 2023 Chronic Coronary Disease guideline recommends a minimum of 6 months of DAPT after drug-eluting stent placement, with extension to 12 months or longer in selected high-ischemic-risk patients with low bleeding risk [4].

Atrial Fibrillation and Combined Therapy

If you also have atrial fibrillation, the combination of oral anticoagulation and antiplatelet therapy requires careful balancing of stroke prevention against bleeding risk. The AUGUSTUS trial (N=4,614) found that apixaban-based regimens with P2Y12 inhibitor monotherapy (without aspirin) produced fewer bleeds and similar ischemic outcomes compared to vitamin K antagonist-based regimens with aspirin [9].

Bring your CHA2DS2-VASc score if you know it. If you do not, your clinician will calculate it at the visit.

Lifestyle Factors: What Your Clinician Will Ask

Prepare honest answers to these questions before you arrive. They affect both risk stratification and medication titration.

Diet and Weight

Your weight and BMI affect eligibility for semaglutide under the SELECT indication. The American Heart Association's 2021 Dietary Guidance recommends a dietary pattern emphasizing whole grains, legumes, non-tropical vegetable oils, lean protein, and minimizing processed meats and sugar-sweetened beverages for cardiovascular risk reduction [19].

Physical Activity Level

The AHA and ACC recommend at least 150 minutes per week of moderate-intensity aerobic activity for secondary cardiovascular prevention [20]. Note your current weekly activity level honestly. If you have exercise-induced chest pain, dyspnea, or syncope, flag this before any exercise prescription is given.

Smoking Status

Smoking cessation after MI reduces all-cause mortality by approximately 36% over five years, an effect size comparable to many pharmacological interventions [21]. If you smoke, your clinician will want to discuss pharmacotherapy (varenicline, bupropion, or nicotine replacement) at this visit.

Symptoms to Report Immediately (Before or During Your Visit)

Some symptoms warrant urgent evaluation, not a scheduled appointment. If you experience any of the following between now and your visit, go to an emergency department or call emergency services:

• Chest pain or pressure lasting more than a few minutes
• Sudden weakness, facial drooping, or speech difficulty (stroke signs)
• New severe shortness of breath at rest
• Palpitations with presyncope or syncope
• Sudden leg pain with pallor or absent pulses (acute limb ischemia)

The ACC/AHA 2023 guideline defines these as class I indications for immediate evaluation [4].

What to Expect During the Appointment Itself

A thorough first cardiovascular visit runs 45-60 minutes. Request this length when you book. The clinician will likely perform a focused physical exam including blood pressure in both arms, heart and lung auscultation, peripheral pulse assessment, and jugular venous pressure estimation.

Likely Diagnostic Orders

Based on what you bring, your clinician may order:

• Resting 12-lead ECG
• Echocardiogram if no recent one exists (<12 months)
• Fasting lipid panel and metabolic panel if labs are outdated
• Exercise stress test or stress imaging if symptoms suggest ischemia
• Ankle-brachial index if PAD is suspected

Medication Changes at the First Visit

Do not be surprised if medications are adjusted at the first visit. Common changes include up-titrating statins to high-intensity, adding ezetimibe, adjusting antihypertensives to reach <130/80 mmHg, or initiating a GLP-1 receptor agonist for CVD risk reduction [5].